Acadian Asset Management
ELVN icon

Acadian Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Acadian Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,825
Closed -$46K – 1776
2024
Q3 		$46K Buy
+1,825
New +$42.3K ﹤0.01% 1810
2022
Q1 		– Sell
-2,148
Closed -$19K – 1677
2021
Q4 		$19K Buy
+2,148
New +$28.2K ﹤0.01% 1613

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Acadian Asset Management's ELVN Position: Q4 2024 in Review

Acadian Asset Management sold out of Enliven Therapeutics (ELVN) in Q4 2024, closing a stake of 1,825 shares — an estimated $46K sold.

Acadian Asset Management first reported a position in ELVN in Q4 2021 and held it in 2 quarters. The position peaked at $46K in Q3 2024. 113 funds tracked by Wall St. Rank hold ELVN as of Q4 2024.

  • Acadian Asset Management reported no remaining Enliven Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 1,825 Enliven Therapeutics shares in Q4 2024, an estimated $46K.
  • Acadian Asset Management first reported a position in Enliven Therapeutics in Q4 2021 and held it in 2 quarters.
  • Acadian Asset Management's Enliven Therapeutics position peaked at $46K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.